BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
SUBSCRIBE
BullScope
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal
No Result
View All Result
BullScope
No Result
View All Result
Home Research Notes

Jushi Holdings: $215 Million in Debt, $31 Million in Cash, and a Bet on Virginia

Moe Alsumidaie by Moe Alsumidaie
November 12, 2026
in Research Notes
0
74
SHARES
1.2k
VIEWS
Share on XShare on LinkedInShare on Facebook

Jushi went public in December 2019 with a simple pitch: buy dispensary licenses in states before adult-use legalization arrived, then ride the wave. For a few years the math looked promising. Then came persistent net losses, a cannabis price collapse that squeezed margins across the industry, and a federal tax code that treated cannabis companies as if they were selling contraband, because legally they were. By the end of 2025, the full-year 10-K showed a company growing its top line while hemorrhaging cash below it. The question heading into 2026 was whether anything structural would change, or whether Jushi would keep running on the same treadmill.

Two things changed. One is a regulatory fact. The other is a bet on a single state.

What matters here

The math, meaning what the filed numbers show, is a business generating real operating cash but carrying debt roughly three times its quarterly revenue, with a cash cushion that covers less than two months of sales. The current market capitalization, relative to the filed revenue and debt figures, implies a valuation that does not appear to embed a significant probability of the Virginia adult-use scenario materializing, a gap readers can assess against the filed projections and balance-sheet constraints. Those two readings sit in genuine tension: if Virginia delivers, the debt load looks manageable; if it doesn’t, the balance sheet has little room for error.

The year’s arc: what the filing shows

The 10-Q filed October 28, 2026, covering the quarter ended September 30, tells a story of modest improvement on almost every operating line. Revenue reached $70.5 million for the quarter, up from $65.7 million a year earlier, the second consecutive quarter above that threshold. The net loss narrowed sharply from the same period a year ago, a meaningful move even if the company is still losing money. Adjusted EBITDA, which strips out non-cash charges and interest to show what the core operations produce before the debt bill arrives, also ticked higher.

BullScope TerminalWant the full evidence sheet behind pieces like this?The terminal runs the complete workup: JUSH and 500+ other names, on the same official data.See the evidence engine →

The detail worth pausing on is wholesale. Wholesale revenue hit a record for the quarter, a roughly forty-percent jump year-over-year. That matters because wholesale is a signal of production efficiency: Jushi is growing enough cannabis to sell to other retailers, not just filling its own shelves. For a company that has historically been almost entirely retail-dependent, a record wholesale quarter suggests the cultivation side is finally pulling its weight.

Gross margin slipped slightly from a year ago, a consequence of competitive pricing pressure across the industry. Think of it this way: for every dollar of cannabis Jushi sells, roughly forty-six cents remain after the cost of growing and processing it. That ratio is holding roughly steady, which is better than many peers have managed in a deflationary market.

The balance sheet: a seven-to-one problem

Here is the contrast that defines Jushi’s situation right now. As of September 30, the company held $30.9 million in cash against gross debt of $215.6 million. That is roughly seven dollars owed for every dollar in the bank, and that ratio is the central structural tension the filing presents.

In March 2026, Jushi completed a debt refinancing, replacing older loans with a new term loan at a double-digit rate, due in 2029. The annual interest bill on that loan alone exceeds what the business earns in operating cash in any single quarter. The refinancing bought time and simplified the covenant structure to a single minimum cash requirement, but it did not reduce the debt load. It extended the runway.

Capital spending for the first nine months of 2026 was modest, with full-year guidance in a similar range. That is a company investing at a measured pace, not aggressively building, which makes sense given the cash position.

BullScope TerminalYou just read JUSH’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →

The two things that changed

The first is federal. On April 24, 2026, the Attorney General ordered that FDA-approved and state-licensed medical cannabis products be rescheduled to Schedule III. On November 3, 2026, Jushi received DEA registrations for certain of its medical cannabis operations under that framework. This matters because Schedule III status eliminates Section 280E for qualifying operations. Section 280E is the tax provision that treats cannabis businesses as drug traffickers, denying them standard business deductions. Removing it for even a portion of Jushi’s operations reduces the effective tax rate on those activities, which flows directly to the bottom line. The full-year impact is not yet filed, but the direction is unambiguous.

The second change is geographic. Virginia is scheduled to open adult-use cannabis sales on July 1, 2027. Jushi operates six dispensaries there, built during the medical-only era. The October earnings release projects that those six stores could generate between $85 million and $160 million in annual retail revenue under adult-use scenarios. To put that range in context: the entire company generated $70.5 million in a single quarter. If Virginia retail revenue landed near the midpoint of management’s $85–$160 million projection, that increment would represent a material share of the company’s current annualized revenue base of roughly $280 million, a scenario readers can weigh against the balance-sheet constraints described above. Jushi is already building a large cultivation warehouse to supply it.

The SAFE Banking Act, which would give cannabis companies access to normal banking services, was reintroduced in June 2026 but remains in committee as of October 2026, according to Herring Bank’s sector tracker. Broader rescheduling of all marijuana products is on hold, per TestSmartly Labs. The regulatory environment is better than it was, but it is not resolved.

Reading the numbers

  • Revenue: $70.5 million (Q3 2026). What it is: total sales across all 42 dispensaries and wholesale channels for the quarter. What it means here: Jushi is growing, but slowly, about 7% faster than a year ago. Everyday terms: a local restaurant chain that did $65 in sales last year is now doing $70 on the same number of tables. Encouraging, not transformative.
  • Adjusted EBITDA: $13.6 million (Q3 2026). What it is: what the operations earn before interest, taxes, depreciation, and non-cash charges, a rough proxy for operating cash generation. What it means here: the business produces real cash, but nearly all of it is consumed by the interest on $215.6 million of debt. Everyday terms: a household earning $1,360 a month but paying roughly $500 in loan interest, about 37% of income, has money left over, but not much, and the principal balance remains enormous.
  • Net loss: $12.5 million (Q3 2026). What it is: what remains after every cost, including interest and taxes, is subtracted from revenue. What it means here: the improvement from $23.7 million a year ago is real and significant, but the company is still consuming cash at the bottom line. Everyday terms: the household’s credit card balance is still growing, just more slowly than last year.
  • Gross debt: $215.6 million vs. cash of $30.9 million. What it is: the gap between what Jushi owes on scheduled repayments and what it holds in liquid assets. What it means here: the margin for error is thin. A bad quarter does not create a crisis immediately, but two or three bad quarters could. Everyday terms: a family with $31,000 in savings and $216,000 on a loan charging 12.5% interest needs everything to go right.

Sources

  • 10-Q, quarter ended September 30, 2026 (SEC EDGAR)
  • 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
  • Jushi Q3 2026 earnings press release, October 28, 2026
  • GlobeNewswire: Jushi Q3 2026 financial results
  • StockTitan: Jushi 8-K, DEA registrations, November 2026
  • DOJ: Schedule III rescheduling announcement, April 2026
  • Investing.com: Jushi Q3 2026 earnings call transcript
  • TestSmartly Labs: DEA rescheduling hold, October 2026
  • Herring Bank: SAFE Banking Act tracker
BullScope publishes impersonal research for a general audience. Nothing here is personalized investment advice, and nothing here is a recommendation to buy or sell any security. As of publication, neither BullScope nor its operator holds a position in any security, covered or otherwise; we do not trade at all, and we accept no compensation from any company we cover. When a conflict of interest exists, we do not publish: companies that compensate our operator in any capacity, or about which our operator could hold nonpublic information, are barred from coverage automatically, as described in the conflicts policy in our methodology. Figures come from company filings and public data through our published methodology; forecasts are conditional scenarios, not predictions and not promises. Markets carry risk, including loss of principal. Consider your own situation, or consult a licensed adviser, before acting on anything you read.
BullScope TerminalYou just read JUSH’s filed numbers.Every claim above traces to a filing. Run any of 500+ companies through the same math-vs-mood engine. Free tier available.Open the Terminal →
Moe Alsumidaie

Moe Alsumidaie

Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.

Recommended For You

Arvinas: the first PROTAC approved, and almost nothing left to show for it

by Moe Alsumidaie
November 13, 2026
0

Five years ago, Arvinas collected $650 million in a single wire transfer from Pfizer, the largest upfront payment any biotech had received for a drug that had not...

Read moreDetails

Iovance: Revenue Is Real, the Losses Are Real, and the Pipeline Just Got More Complicated

by Moe Alsumidaie
November 11, 2026
0

For most of its life, Iovance Biotherapeutics was a research project wearing a company's clothes. It spent years and hundreds of millions of dollars teaching the immune system...

Read moreDetails

Merck Is Spending Like It Has a Problem. The Filed Numbers Say It Does.

by Moe Alsumidaie
November 11, 2026
0

For most of the last decade, Merck ran a tidy business: one blockbuster drug, Keytruda, growing fast enough to carry everything else. Then 2026 arrived, and the company...

Read moreDetails

Ligand Pharmaceuticals: Royalties Are Surging. The Stock Price Assumes They Never Stop.

by Moe Alsumidaie
November 6, 2026
0

Ligand spent most of the last decade shedding things. It spun off its antibody discovery unit in November 2022, sold assets, and narrowed toward a single idea: own...

Read moreDetails

Harrow: Revenue Doubles, Equity Nearly Vanishes, and the Stock Is Down by Half

by Moe Alsumidaie
November 11, 2026
0

The quick read Harrow's filed numbers show revenue growing at a pace most pharmaceutical companies never see, more than fivefold in five years. The 10-Q filed for the...

Read moreDetails
Next Post

CorMedix's Reimbursement Cliff Meets a $145 Million Bet: What the Call Said, What the Filing Confirmed

Please login to join discussion
BullScope
The Research Terminal
Run any stock through the BullScope evidence engine. Filings in, evidence out. Every number explains itself.
Open the Terminal
A BullScope product

Related News

Costco’s Membership Machine: The Fee That Runs the Whole Show

July 21, 2026

Evidence Sheet: Biogen (BIIB)

October 29, 2026

Evidence Sheet: Vertex Pharmaceuticals Inc / Ma (VRTX)

November 4, 2026
BullScope

BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.

Prefer BullScope.ai on Google

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

No Result
View All Result
  • Home
  • Market News
  • Bargains & Bubbles
  • Expectations Audits
  • Research Notes
  • Said vs. Filed
  • The Economy
  • Evidence Sheets
  • Research Terminal

© 2026 BullScope. Evidence-first investment research. Not investment advice.  ·  Methodology  ·  Privacy Policy  ·  Terms of Use  ·  Disclaimer

Not enough quota to unlock this post
Unlock left : 0
Are you sure want to cancel subscription?
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.